Mia (Mammography Intelligent Assessment)
A London-built breast screening AI trialled across NHS sites as a second reader, now folded into RadNet's DeepHealth after a 2024 acquisition.
Overview
Kheiron Medical Technologies (founded in London in 2016) received the CE mark for Mia in 2019 and won an NHS AI in Health and Care Award in 2020, which funded prospective evaluation of Mia as an independent second reader in NHS breast screening units, including a widely reported service evaluation in NHS Grampian. Retrospective multi-site studies in the UK and Hungary reported non-inferior performance to human readers. In 2024 Kheiron became part of DeepHealth, RadNet's AI subsidiary, and Mia's technology was integrated into DeepHealth's SmartMammo. The UK's national evaluation of AI in breast screening (the EDITH trial, announced 2025) will test several products at scale.
Approvals
| Region | Year | Indication |
|---|---|---|
| EU | 2019 | CE mark, mammography decision support |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Notes
top- What a result means: in the NHS the AI would replace one of two human readers; discordant cases go to arbitration by a radiologist, as now.
Latest papers
topQuery for this drug: (TITLE:"Mia" OR ABSTRACT:"Mia" OR TITLE:"Mammography Intelligent Assessment" OR ABSTRACT:"Mammography Intelligent Assessment") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Mia (Mammography Intelligent Assessment), not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductLunit INSIGHT MMG
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
- ProductProFound AI (iCAD)
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
- ProductTranspara
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
- ProductRaDaR
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
- ProductOptellum Virtual Nodule Clinic
Shares AI in radiology and the tag test.
- ProductBRACAnalysis CDx
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
- ProductBreast Cancer Index
Shares HR-positive / HER2-negative breast cancer and the tag test.
- ProductEndoPredict
Shares HR-positive / HER2-negative breast cancer and the tag test.